Tiburio Therapeutics Inc., a clinical stage company developing therapies for rare endocrine diseases, today published new data from a preclinical study in the Journal of the Endocrine Society demonstrating that its lead clinical asset, TBR-760, a dopamine somatostatin chimeric compound, arrests aggressive non-functioning pituitary adenoma (NFPA) growth in a mouse model. The pre-clinical data indicate that TBR-760 completely arrested tumor growth in the pro-opiomelanocortin (POMC) gene knock-out (KO) mouse model of NFPA. Additionally, notable tumor shrinkage was observed in 20% of the mice treated with TBR-760.
Tiburio Therapeutics was included in BioSpace's annually curated NextGen Bio Class, which showcases twenty top life sciences companies in North America formed since 2018 that are already making an impact in the industry. Since our launch in 2020, we at Tiburio are proud of our commitment to develop pharmaceutical treatment options for patients living rare neuroendocrine disease. We are honored to join BioSpace's NextGen Bio Class of 2020, and we congratulate this year's other honorees!
Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and endocrine diseases, today announced the appointment of Nerissa Kreher, MD, to the newly created position of Chief Medical Officer. Dr. Kreher brings 13 years of experience in medical affairs and clinical development from leading biotechnology companies, most recently serving as Chief Medical Officer at AVROBIO, a gene therapy company. There, she led all clinical development and clinical operations for multiple global rare disease programs, including programs for Fabry and Gaucher disease, among others.
Cydan today announced the launch of Tiburio Therapeutics Inc. (Tiburio), a private biopharmaceutical company focused on developing treatments for rare neuroendocrine tumors and rare endocrine diseases. Tiburio will advance two compounds licensed from Ipsen for the treatment of non-functioning pituitary adenoma (NFPA) (TBR-760) and for additional rare endocrine diseases (TBR-065). As part of the launch, Tiburio raised a $31M Series A financing that will fund the company’s lead compound, TBR-760, through human proof-of-concept for the treatment of NFPA and further clinical assessment of TBR-065 as a treatment for rare endocrine diseases. In conjunction with the Tiburio financing, Abraham N. Ceesay has been appointed chief executive officer of the company.
In the News
Drug Development & Delivery
Pituitary World News Podcast
Empowered Patient Podcast